India · Delayed Price · Currency is INR Jubilant Pharmova Statistics
Total Valuation
NSE:JUBLPHARMA has a market cap or net worth of INR 152.48 billion. The enterprise value is 175.98 billion.
| Market Cap | 152.48B |
| Enterprise Value | 175.98B |
Important Dates
The last earnings date was Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
| Current Share Class | 158.39M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.04% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 7.67% |
| Owned by Institutions (%) | 21.44% |
| Float | 64.25M |
Valuation Ratios
The trailing PE ratio is 43.31 and the forward PE ratio is 31.04.
| PE Ratio | 43.31 |
| Forward PE | 31.04 |
| PS Ratio | 1.77 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 5.10 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 12.43 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 49.98 |
| EV / Sales | 2.04 |
| EV / EBITDA | 16.40 |
| EV / EBIT | 23.27 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 3.37 |
| Debt / FCF | -16.26 |
| Interest Coverage | 3.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 5.16% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | 15.23M |
| Profits Per Employee | 622,415 |
| Employee Count | 5,547 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:JUBLPHARMA has paid 1.95 billion in taxes.
| Income Tax | 1.95B |
| Effective Tax Rate | 35.65% |
Stock Price Statistics
The stock price has decreased by -15.67% in the last 52 weeks. The beta is 0.51, so NSE:JUBLPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -15.67% |
| 50-Day Moving Average | 970.53 |
| 200-Day Moving Average | 984.14 |
| Relative Strength Index (RSI) | 40.65 |
| Average Volume (20 Days) | 173,716 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JUBLPHARMA had revenue of INR 86.16 billion and earned 3.52 billion in profits. Earnings per share was 22.17.
| Revenue | 86.16B |
| Gross Profit | 56.01B |
| Operating Income | 7.57B |
| Pretax Income | 5.46B |
| Net Income | 3.52B |
| EBITDA | 10.73B |
| EBIT | 7.57B |
| Earnings Per Share (EPS) | 22.17 |
Balance Sheet
The company has 12.67 billion in cash and 36.15 billion in debt, with a net cash position of -23.48 billion.
| Cash & Cash Equivalents | 12.67B |
| Total Debt | 36.15B |
| Net Cash | -23.48B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 70.96B |
| Book Value Per Share | 447.81 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 12.27 billion and capital expenditures -14.49 billion, giving a free cash flow of -2.22 billion.
| Operating Cash Flow | 12.27B |
| Capital Expenditures | -14.49B |
| Depreciation & Amortization | 3.17B |
| Net Borrowing | 4.31B |
| Free Cash Flow | -2.22B |
| FCF Per Share | n/a |
Margins
Gross margin is 65.01%, with operating and profit margins of 8.78% and 4.09%.
| Gross Margin | 65.01% |
| Operating Margin | 8.78% |
| Pretax Margin | 6.34% |
| Profit Margin | 4.09% |
| EBITDA Margin | 12.46% |
| EBIT Margin | 8.78% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.54%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 0.54% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.04% |
| Shareholder Yield | 0.58% |
| Earnings Yield | 2.31% |
| FCF Yield | -1.46% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:JUBLPHARMA is 1,099.00, which is 13.30% higher than the current price. The consensus rating is "Hold".
| Price Target | 1,099.00 |
| Price Target Difference | 13.30% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.
| Last Split Date | Mar 17, 2006 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |